Impact of microRNAs in resistance to chemotherapy and novel targeted agents in non-small cell lung cancer.
Despite recent advances in understanding the cancer signaling pathways and in developing new therapeutic strategies, non-small cell lung cancer (NSCLC) shows grim prognosis and high incidence of recurrence. Insufficient disruption of oncogenic signaling and drug resistance are the most common causes of tumor recurrence. Drug resistance, intrinsic or acquired, represents a main obstacle in NSCLC therapeutics by limiting the efficacy both of conventional chemotherapeutic compounds and new targeted agents. Therefore, novel and more innovative approaches are required for treatment of this tumor. MicroRNAs (miRNAs) are a family of small non-coding RNAs that regulate gene expression by sequence-specific targeting of mRNAs causing mRNA degradation or translational repression. Accumulating evidence suggests that impairment of candidate miRNAs may be involved in the acquisition of tumor cell resistance to conventional chemotherapy and novel biological agents by affecting the drug sensitivity of cancer cells. The modulation of these miRNAs, using antagomiRs or miRNA mimics, can restore key gene networks and signaling pathways, and optimize anticancer therapies by inhibition of tumor cell proliferation and increasing the drug sensitivity. Therefore, miRNA-based therapeutics provides an attractive anti-tumor approach for developing new and more effective individualized therapeutic strategies, improving drug efficiency, and for predicting the response to different anticancer drugs. In this review, we present an overview on the role of miRNAs in resistance mechanisms of NSCLC, discussing the main studies on the aberrations in apoptosis, cell cycle and DNA damage repair pathways, as well as in novel drug targets.
Christian
C
Rolfo
Daniele
D
Fanale
David S
DS
Hong
Apostolia M
AM
Tsimberidou
Sarina A
SA
Piha-Paul
Patrick
P
Pauwels
Jan P
JP
Van Meerbeeck
Stefano
S
Caruso
Viviana
V
Bazan
Giuseppe
G
Cicero
Antonio
A
Russo
Department of Medical Oncology, VU University Medical Center, Cancer Center Amsterdam, CCA room 1.42, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands. e.giovannetti@vumc.nl.
Elisa
E
Giovannetti
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000235:genetics; D019008:Drug Resistance, Neoplasm / Q000187:drug effects*; D006801:Humans; D035683:MicroRNAs / Q000378:metabolism*
D000970:Antineoplastic Agents; D035683:MicroRNAs